Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.

Ana Elena Martín-AguilarHaidé Núñez-LópezJuan Carlos Ramírez-Sandoval

Published in: BMC cancer (2021)

Sequential inhibition of VEGF with sorafenib as a second-line treatment may benefit patients with metastatic RCC, especially in subjects > 65 years old.

Keyphrases

metastatic renal cell carcinoma
endothelial cells
vascular endothelial growth factor
combination therapy
smoking cessation